Public Release: 

Rare brain disease in children: Major breakthroughs in Rasmussen's encephalitis

University of Montreal

MONTREAL, April 9, 2018 - Chronic focal encephalitis, or Rasmussen's encephalitis, is a rare and devastating inflammatory brain disease that can lead to the destruction or removal of a part of the affected child's brain. Through experiments on humanized mice, a team of researchers from Université de Montréal and the CHU Sainte-Justine and Université de Montréal Hospital (CHUM) research centres has recently proven what scientists had already suspected: the disease is autoimmune, which means that it attacks patients using their own immune system.

"Several treatments have been proposed to slow the progression of the disease in affected children; however, these treatments have produced contradictory results, particularly in the long term," explains the study's co-author, Dr. Alexandre Prat, a professor of neuroscience at Université de Montréal and researcher at the Centre de recherche du CHUM. "In addition to shedding light on the autoimmune origins of the disease, we have proven that experimenting on humanized mice allows for a more precise diagnosis. This is especially helpful since there are no biological markers for Rasmussen's encephalitis, which makes diagnosing it difficult in certain children. These mice could therefore be useful for testing various treatments and determining the best one for each individual patient. We call this 'personalized' or 'precision' medicine."

Discovered by Théodore Rasmussen (1910-2002), a neurosurgeon who specialized in treating epilepsy, chronic focal encephalitis is a degenerative affliction that most often develops in children. Its causes are unknown. The disease is characterized by recurring epileptic seizures that resist conventional antiepileptic treatments. In more serious cases, the frequency of the seizures can only be reduced by disconnecting the two hemispheres of the brain or by removing one of them and dealing with the neurological consequences. As the disease progresses, it triggers cognitive decline and severe learning disabilities. In Canada, up to two cases of Rasmussen's encephalitis are diagnosed each year.

Using humanized mice to study rare diseases

This is where Elie Haddad and Lionel Carmant, professors in the Department of Pediatrics at UdeM and researchers at CHU Sainte-Justine, take centre stage. "Rasmussen's encephalitis is one of those diseases that are so rare that scientists are unable to find enough patients to study it and conduct clinical trials," Dr. Carmant explains. "What's more, no animals are known to suffer from it, so researches can't look there for answers either."

However, thanks to advances in research, NSG™ mice, a type of humanized mice, are helping researchers, and may soon help children with Rasmussen's encephalitis. First developed in laboratories in 2000, humanized mice lack an immune system. They are used to study the human immune system and illnesses such as cancer, leukemia, HIV and sometimes certain allergies and inflammatory diseases.

In his lab at the Centre de recherche du CHU Sainte-Justine, Dr. Haddad uses humanized mice to research cancer and immunotherapy treatments, offering a promising lead in the fight against cancer. Dr. Carmant called upon Dr. Haddad's expertise and together they came up with the idea to use these valuable humanized mice to study chronic focal encephalitis.

"We introduced immune cells from patients with Rasmussen's encephalitis into the mice; because these rodents don't have an immune system, they are unable to reject the cells," Dr. Haddad explains. "We then observed the mice, who developed violent convulsions and brain necrosis, just like their human counterparts. Biopsies of the mice's brains revealed immunological damage that was practically identical to that in human patients, which proves the disease's immunological origins."

A hope for better lives for affected children

The hope inspired by this research on humanized mice stems from the newfound possibility of using these animals for making diagnoses as early as possible and selecting the best treatment for each sick child. If patients receive the proper treatment early, it is possible to avoid the cognitive decline brought on by the disease and forestall the need for brain surgery (hemispherectomy).

"The next step is to use NSG™ mice to design a standardized diagnostic protocol that can be used in pediatric hospitals," says Dr, Prat. "These mice will become patient surrogates for making diagnoses and establishing personalized treatment protocols."


About the study

Hania Kebir, Lionel Carmant et al., "Humanized mouse model of Rasmussen's encephalitis supports the immune-mediated hypothesis", Journal of Clinical Investigation, April 9, 2018.

This study was funded by the RE Foundation and the Canadian Institutes of Health Research.

About Université de Montréal

Université de Montréal and its two affiliated schools, École Polytechnique (engineering) and HEC Montréal (business), are amongst the world's top universities, according to international rankings. Founded in 1878, the campus today has over 67,000 students and 2,700 professors, making Université de Montréal the second largest university in Canada. Its students are drawn to the university by its deep roots in cosmopolitan Montreal and in consideration of its tenacious dedication to its international mission.

About Université de Montréal Hospital Research Centre

The Université de Montréal Hospital Research Centre (CRCHUM) improves the health of adults through a high-quality academic research continuum which, by improving our understanding of etiological and pathogenic mechanisms, fosters the development, implementation, and assessment of new preventive, diagnostic and therapeutic strategies. The CRCHUM provides a training environment to ensure the development of new generations of researchers committed to research excellence.

About CHU Sainte-Justine Research Centre

CHU Sainte-Justine Research Centre is a leading mother-child research institution affiliated with Université de Montréal. It brings together more than 200 research investigators, including over 90 clinicians, as well as 350 graduate and post-graduate students focused on finding innovative means of prevention, faster and less invasive treatments, and personalized approaches to medicine. The Centre is part of CHU Sainte-Justine, which is the largest mother-child hospital in Canada and second most important pediatric hospital in North America.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.